Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Down-regulator of transcription 1 (DR1) is a TBP (TATA box-binding protein)-associated phosphoprotein that functions as a transcriptional repressor, affecting both basal and activated RNA polymerase II-dependent gene expression. DR1 contains a histone fold motif, TBP-binding domain, and a glutamine/alanine-rich region. It regulates transcription by binding TBP and forming a heterodimer with DRAP1, inhibiting assembly of the transcription preinitiation complex. Additionally, DR1 is a component of the ATAC complex, which has histone acetyltransferase activity. The protein influences chromatin organization and may open new directions for targeted drug discovery, though no established drugs directly interact with DR1 yet.
Transcriptional repression via interaction with TATA-binding protein (TBP) and formation of repressor complexes (with DRAP1), which block assembly of preinitiation complexes and the association of other transcription factors (TFIIA/TFIIB) with TBP. Modulation of chromatin/histone acetylation status (via ATAC complex).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Down-regulator of transcription 1 (DR1).